澳大利亚痴呆症的诊断挑战：基于血液的生物标志物是解决方案吗？
Diagnostic challenges for dementia in Australia: are blood-based biomarkers the solution?
机构信息
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Department of Medical Biology, The University of Melbourne, Melbourne, Victoria, Australia.
出版信息
Intern Med J. 2022 Dec;52(12):2181-2185. doi: 10.1111/imj.15973.
Abstract
The burden of dementia will increase as the Australian population ages and grows in coming decades. Early and accurate diagnosis remains challenging, and disproportionately so for particular groups, including rural communities. Recent advances in technology, however, now allow reliable measurement of blood biomarkers that could improve diagnosis in a range of settings. We discuss the most promising biomarker candidates for translation into clinical practice and research in the near future.
摘要
随着澳大利亚人口老龄化和未来几十年的增长，痴呆症的负担将会增加。早期和准确的诊断仍然具有挑战性，对于某些特定群体，包括农村社区，更是如此。然而，最近的技术进步现在可以可靠地测量血液生物标志物，这可以提高一系列环境下的诊断水平。我们讨论了最有前途的生物标志物候选物，以在不久的将来转化为临床实践和研究。
相似文献
1
Diagnostic challenges for dementia in Australia: are blood-based biomarkers the solution?澳大利亚痴呆症的诊断挑战：基于血液的生物标志物是解决方案吗？
Intern Med J. 2022 Dec;52(12):2181-2185. doi: 10.1111/imj.15973.
2
Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans.通过澳大利亚痴呆症网络（ADNeT）共同应对痴呆症：计划、进展与倡议概述。
J Alzheimers Dis. 2023;96(3):913-925. doi: 10.3233/JAD-230854.
3
Diagnosis of dementia in Australia: a narrative review of services and models of care.澳大利亚的痴呆症诊断：服务与护理模式的叙述性综述
Aust Health Rev. 2019 Aug;43(4):415-424. doi: 10.1071/AH17167.
4
Influence of rurality on diagnosing dementia in Australian general practice.澳大利亚全科医疗中乡村地区对痴呆症诊断的影响。
Aust J Prim Health. 2012;18(3):178-84. doi: 10.1071/PY12008.
5
Challenges, solutions and future directions for public health innovations targeting dementia prevention for rural and remote populations.针对农村和偏远地区人口的痴呆预防的公共卫生创新的挑战、解决方案和未来方向。
Australas J Ageing. 2022 Sep;41(3):466-472. doi: 10.1111/ajag.13105. Epub 2022 Jul 17.
6
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.超越黑木树：影响澳大利亚地区、农村和偏远地区的健康研究问题的快速综述。
Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881.
7
Fluid Biomarkers in Dementia Diagnosis.痴呆症诊断中的液体生物标志物。
Continuum (Minneap Minn). 2022 Jun 1;28(3):822-833. doi: 10.1212/CON.0000000000001083.
8
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early detection of dementia across a variety of healthcare settings.用于在各种医疗保健环境中早期发现痴呆症的老年人认知减退信息问卷 (IQCODE)。
Cochrane Database Syst Rev. 2021 Jul 18;7(7):CD011333. doi: 10.1002/14651858.CD011333.pub3.
9
Understanding diagnostic settings and carer experiences for dementia diagnosis in Australia.了解澳大利亚痴呆症诊断的诊断设置和照护者体验。
Intern Med J. 2021 Jul;51(7):1126-1135. doi: 10.1111/imj.14869.
10
Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach.路易体痴呆新型脑脊液生物标志物候选物的鉴定：蛋白质组学方法
Mol Neurodegener. 2020 Jun 18;15(1):36. doi: 10.1186/s13024-020-00388-2.
引用本文的文献
1
Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.在诊断异质性临床队列中，血浆ptau217对脑脊液生物标志物定义的早发性阿尔茨海默病具有强大的诊断性能。
J Neurol. 2024 Dec 12;272(1):25. doi: 10.1007/s00415-024-12732-3.
本文引用的文献
1
Tau as a Biomarker of Neurodegeneration.tau 作为神经退行性变的生物标志物。
Int J Mol Sci. 2022 Jun 30;23(13):7307. doi: 10.3390/ijms23137307.
2
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.脑脊液神经丝轻链在临床环境中可将原发性精神障碍与快速进展性阿尔茨海默病和额颞叶痴呆区分开来。
Alzheimers Dement. 2022 Nov;18(11):2218-2233. doi: 10.1002/alz.12549. Epub 2022 Feb 1.
3
A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study.神经科医生对记忆门诊中血清神经丝轻链的看法：一项前瞻性实施研究。
Alzheimers Res Ther. 2021 May 18;13(1):101. doi: 10.1186/s13195-021-00841-4.
4
Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre-analytical conditions.偏远地区的血液神经丝轻链检测：在具有挑战性的分析前条件下支持样本采集的替代方案
Alzheimers Dement (Amst). 2021 Feb 20;13(1):e12145. doi: 10.1002/dad2.12145. eCollection 2021.
5
Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis.路易体痴呆症中 tau 的患病率及临床相关性：系统评价和荟萃分析。
Parkinsonism Relat Disord. 2020 Nov;80:184-193. doi: 10.1016/j.parkreldis.2020.09.030. Epub 2020 Sep 23.
6
Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease.阿尔茨海默病可靠血液检测取得快速进展。
JAMA Neurol. 2021 Feb 1;78(2):143-145. doi: 10.1001/jamaneurol.2020.4200.
7
Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.用于鉴别额颞叶痴呆和路易体痴呆与阿尔茨海默病的新型体液生物标志物：一项系统评价
J Neurol Sci. 2020 Aug 15;415:116886. doi: 10.1016/j.jns.2020.116886. Epub 2020 May 11.
8
The application of telehealth to remote and rural Australians with chronic neurological conditions.远程和农村地区患有慢性神经疾病的澳大利亚人对远程医疗的应用。
Intern Med J. 2021 Jul;51(7):1043-1048. doi: 10.1111/imj.14841.
9
Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg.神经退行性疾病中的液体生物标志物研究展望——2019 年 UCL 和哥德堡大学神经退行性疾病生物标志物博士生联合课程。
Alzheimers Res Ther. 2020 Feb 28;12(1):20. doi: 10.1186/s13195-020-00586-6.
10
The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis.脑脊液和血液中神经丝轻链对阿尔茨海默病、额颞叶痴呆和肌萎缩侧索硬化症的诊断性能：一项系统评价和荟萃分析。
Alzheimers Dement (Amst). 2019 Nov 4;11:730-743. doi: 10.1016/j.dadm.2019.08.009. eCollection 2019 Dec.
Zotero 插件